Study links Agent Orange exposure to neurodegenerative diseases

No­var­tis shelved a Phase II pro­gram it was test­ing for obe­si­ty-re­lat­ed dis­eases af­ter find­ing a lack of ef­fi­ca­cy, the phar­ma gi­ant dis­closed Tues­day in its

Wracked with qual­i­ty ques­tion marks that have caused ma­jor short­ages of com­mon can­cer drugs, In­dia-based gener­ic drug man­u­fac­tur­er In­tas Phar­ma­ceu­ti­cals has been hand­ed a warn­ing